AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- McKesson reports cybersecurity incident affecting its information systems
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
Abbvie (ABBV) PT Raised to $154 at BMO Capital
February 3, 2022 7:19 AM ESTBMO Capital analyst Gary Nachman raised the price target on Abbvie (NYSE: ABBV) to $154.00 (from $153.00) while maintaining an Outperform rating.
The analyst commented, "4Q good overall despite slight revenue shortfall as many key growth drivers performed well and better op. leverage drove EPS... More
AbbVie (ABBV) Tops Q4 EPS by 3c, Offers Guidance
February 2, 2022 7:44 AM ESTAbbVie (NYSE: ABBV) reported Q4 EPS of $3.31, $0.03 better than the analyst estimate of $3.28. Revenue for the quarter came in at $14.89 billion versus the consensus estimate of $14.95 billion.
GUIDANCE:
AbbVie sees FY2022 EPS of $14.00-$14.20, versus the consensus of... More
